Radioactive Shrimp, Ozempic Allegations: The MedPage Today Culture AwardsRadioactive Shrimp, Ozempic Allegations: The MedPage Today Culture Awards
(MedPage Today) — We’ve nominated medicine’s biggest culture makers and moments of 2025, it’s your turn to vote (MedPage Today) — We’ve nominated medicine’s biggest culture makers and moments of 2025, it’s your turn to vote
Costs for Zepbound, Wegovy Could Drop Soon: What to KnowCosts for Zepbound, Wegovy Could Drop Soon: What to Know
The White House is in discussions with the makers of weight loss drugs Wegovy and Zepbound to drastically lower prices, NBC News has learned. The prices could drop from an average price of $1,300 a month to $150 a month, according to sources familiar with the plan. It remains unclear who would be eligible. NBC’s Read More
Common heartburn and blood pressure medicines linked to adverse breast cancer outcomes in large global studyCommon heartburn and blood pressure medicines linked to adverse breast cancer outcomes in large global study
A major international study involving 23,000 people has found concerning evidence about the impact of a range of common, everyday medications on the treatment outcomes for patients with breast cancer.
Wegovy in a pill? Massive weight loss results revealedWegovy in a pill? Massive weight loss results revealed
Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels. With a safety profile consistent with existing treatments, experts see it as a breakthrough for patients preferring oral options. Novo Nordisk’s oral semaglutide 25 mg Read More
Radiation May Be Unnecessary for Many Breast Cancer PatientsRadiation May Be Unnecessary for Many Breast Cancer Patients
Doctors have already begun reducing radiation treatment for women at low risk of recurrence or spread of the disease. A new study finds that some women at greater risk can safely avoid radiation.
Advanced breast cancer patients living longer thanks to improvements in treatment and careAdvanced breast cancer patients living longer thanks to improvements in treatment and care
People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the average survival time for patients diagnosed in 2011, according to a major study of patient data in the US presented at the Advanced Breast Cancer Eighth International Consensus Conference (ABC8).
Global survey highlights challenges faced by young women with advanced breast cancerGlobal survey highlights challenges faced by young women with advanced breast cancer
Nearly half of all women aged younger than 40 who live with advanced breast cancer have children under the age of 18, according to the first global survey to investigate the challenges these women face. Results from the survey were presented to the Advanced Breast Cancer Eighth International Consensus Conference (ABC8).
Global Decade Report reveals breakthroughs in advanced breast cancer but exposes a widening global equity gapGlobal Decade Report reveals breakthroughs in advanced breast cancer but exposes a widening global equity gap
The ABC Global Alliance today launched the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025—a global assessment revealing a decade of remarkable scientific progress that has transformed ABC care for some patients in some countries, while many others around the world have yet to benefit.
Existing drug could reduce breast cancer risk in pre-menopausal womenExisting drug could reduce breast cancer risk in pre-menopausal women
A University of Manchester study reveals a drug approved for use in other conditions could be repurposed as a preventive breast cancer treatment in women before menopause.
Macrophage ‘bodyguard’ disruptors may help overcome hormone-resistant breast cancerMacrophage ‘bodyguard’ disruptors may help overcome hormone-resistant breast cancer
In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have tested a new combination therapy for hormone-resistant, estrogen receptor-positive (ER+) breast cancer and were able to shrink tumors, reduce the number of cancer stem cells and reprogram the immune environment to be less supportive of cancer growth.